Fintel reports that on August 16, 2023, Capital One initiated coverage of Immunocore Holdings plc - ADR (NASDAQ:IMCR) with a Overweight recommendation.
Analyst Price Forecast Suggests 35.31% Upside
As of August 2, 2023, the average one-year price target for Immunocore Holdings plc - ADR is 81.52. The forecasts range from a low of 67.67 to a high of $96.60. The average price target represents an increase of 35.31% from its latest reported closing price of 60.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunocore Holdings plc - ADR is 178MM, a decrease of 2.15%. The projected annual non-GAAP EPS is -0.57.
What is the Fund Sentiment?
There are 222 funds or institutions reporting positions in Immunocore Holdings plc - ADR. This is an increase of 18 owner(s) or 8.82% in the last quarter. Average portfolio weight of all funds dedicated to IMCR is 0.47%, a decrease of 1.03%. Total shares owned by institutions increased in the last three months by 16.73% to 39,423K shares. 
The put/call ratio of IMCR is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 6,030K shares representing 12.32% ownership of the company. In it's prior filing, the firm reported owning 5,650K shares, representing an increase of 6.30%. The firm increased its portfolio allocation in IMCR by 18.33% over the last quarter.
Wellington Management Group Llp holds 3,695K shares representing 7.55% ownership of the company. In it's prior filing, the firm reported owning 3,375K shares, representing an increase of 8.66%. The firm decreased its portfolio allocation in IMCR by 82.12% over the last quarter.
Rock Springs Capital Management holds 3,028K shares representing 6.19% ownership of the company. In it's prior filing, the firm reported owning 3,002K shares, representing an increase of 0.88%. The firm increased its portfolio allocation in IMCR by 22.01% over the last quarter.
Baker Bros. Advisors holds 2,521K shares representing 5.15% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 2,423K shares representing 4.95% ownership of the company. In it's prior filing, the firm reported owning 1,383K shares, representing an increase of 42.91%. The firm increased its portfolio allocation in IMCR by 97.74% over the last quarter.
Immunocore Holdings Background Information
(This description is provided by the company.)
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
Additional reading:
- Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements
- MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
